Healio reports that a study involving ASCO and the nonprofit advocacy group Friends of Cancer Research have issued recommendations to expand clinical trial access. These recommendations include the expanding of eligibility criteria which the study authors believe would double the number of non-small lung cell patients available to participate in clinical trials. The research was recently presented at ASCO.
Comments from Winship Cancer Institute:
Donald Harvey, PharmD, BCOP, FCCP, FHOPA, director of the Winship Cancer Institute’s Phase 1 clinical trials section and associate professor at Emory University School of Medicine noted, “it will accelerate accrual to these clinical trials and will bring new therapies to these patients more quickly.”
Follow the link to the source for more details.